Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1097

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 1097
---
2024:

    Name 
    Fees
    Earned or Paid in Cash ($)  
    Stock
    Awards ($)  
    Option
    Awards ($) (1)  
    Non-Equity
    Incentive Plan Compensation ($)  
    Change
    in Pension Value and Nonqualified Deferred Compensation Earnings ($)  
    All
    Other Compensation ($)  
    Total
    ($) 
  
    Matthew
    Whalen 
     -  
         -  
     16,525  
                 -  
             -  
             -  
     - 
  
    Mathew
    Paul Del Giudice 
     -  
     -  
     69,775  
     -  
     -  
     -  
     69,775 
  
    Denil
    Shekhat 
     -  
     -  
     117,400  
     -  
     -  
     -  
     117,400 
  
    Edward
    MacPherson 
     -  
     -  
     69,775  
     -  
     -  
     -  
     69,775 
  
    Dr.
    Christopher Chapman 
     24,121  
     -  
     -  
     -  
     -  
     -  
     - 

    (1)
    The
    reported amounts represent the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards
    Board Account Standards Codification Topic 718, Stock Compensation, as modified or supplemented, or FASB ASC Topic 718. The assumptions
    used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 8 to our Consolidated
    Financial Statements for the year ended December 31, 2022 included in this Report.

Christopher
Chapman

On
April 28, 2023, we entered into an employment agreement with Dr. Chapman, as amended on August 28, 2023, and October 13, 2023, pursuant
to which Dr. Chapman served as our Executive Chairman. Dr. Chapman’s employment agreement, as amended, provided that his employment
would be on a part-time basis